BIOMAT Database Logo BIOMAT Database Logo

Use of magnesium hydroxide and low magnesium dialysate does not permit reduction of aluminum hydroxide during continuous ambulatory peritoneal dialysis. 1986

A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey

In an effort to reduce the ingestion of aluminum in phosphate-binding antacids, we treated seven patients on continuous ambulatory peritoneal dialysis (CAPD) with low magnesium dialysate and phosphate binders containing both aluminum and magnesium hydroxide. The total amount of phosphate binders prescribed was adjusted to maintain the serum phosphorus at normal levels. The dose of magnesium hydroxide was limited by intolerable gastrointestinal side effects in six of the seven patients. One patient also developed symptomatic hypermagnesemia. When magnesium hydroxide was prescribed in tolerable doses, the mean aluminum dose was not significantly decreased compared with the dose when taking aluminum hydroxide alone. We conclude that substitution of magnesium hydroxide for aluminum hydroxide as a phosphate binder fails to reduce the dose of aluminum in most patients on CAPD.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008276 Magnesium Hydroxide An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects. Brucite,Magnesium Hydrate,Magnesium Hydroxide (Mg(OH)4),Hydrate, Magnesium,Hydroxide, Magnesium
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas

Related Publications

A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Effects of a magnesium-free dialysate on magnesium metabolism during continuous ambulatory peritoneal dialysis.
October 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
[Neutralized continuous ambulatory peritoneal dialysis dialysate].
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Does low-calcium dialysate accelerate secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients?
January 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Magnesium and parathyroid hormone changes to magnesium-free dialysate in continuous ambulatory peritoneal dialysis patients.
January 1994, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
June 2002, The Korean journal of internal medicine,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Magnesium homeostasis in patients undergoing continuous ambulatory peritoneal dialysis: role of the dialysate magnesium concentration.
September 2003, Artificial organs,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Diabetes, dialysate losses, and serum lipids during continuous ambulatory peritoneal dialysis.
August 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Serum aluminum and continuous ambulatory peritoneal dialysis.
January 1980, Annals of internal medicine,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patients.
November 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A E Jennings, and M Bodvarsson, and G Galicka-Piskorska, and A S Diefendorf, and G M Simon, and A S Levey
Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis.
January 1980, Transactions - American Society for Artificial Internal Organs,
Copied contents to your clipboard!